智通财经网·2025-08-05 08:11Group 1 - The stock price of Junshi Biosciences (01877) surged nearly 35%, reaching HKD 32.28 with a trading volume of HKD 1.25 billion [1] - Guotai Junan Securities reported a growing enthusiasm for dual-antibody development globally, indicating a window for innovative achievements in the domestic antibody industry [1] - Junshi Biosciences has extensive experience in monoclonal antibody development, with its PD-1 monoclonal antibody, Toripalimab, being one of the first domestically launched PD-1 inhibitors [1] Group 2 - Toripalimab is currently approved for multiple indications in China and is expanding its global commercialization network, with approvals expected in the US and EU in 2023 and 2024 [1] - The company has developed a series of innovative dual-antibody molecules (JS207, JS201, JS203, JS205) and dual-antibody ADCs (JS212) [1] - On June 20, Junshi Biosciences completed a placement of 41 million new shares, raising approximately HKD 1.026 billion, with 70% of the funds allocated for innovative drug research and 30% for general corporate purposes [1]